Hepatitis B and C Diagnostics Market Size to grow by USD 2,055.79 million between 2023-2027
According to a research report “ Hepatitis B and C Diagnostics Market” by Type (Immunodiagnostics, NAT) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2027 published by Technavio, the market size is estimated to grow by USD 2,055.79 million, at a CAGR of 6.12% during the forecast period. The global diagnostics market for Hepatitis B and C is experiencing significant growth due to the increasing demand for molecular diagnostics. Approximately 800 laboratories, including 600 hospitals and 200 independent laboratories, perform high-volume testing for these viruses. Automated molecular diagnostic platforms are essential for simplifying and facilitating sample preparation in these tests. Real-time Polymerase Chain Reaction (PCR) is the preferred molecular diagnostics method for detecting HCV RNA and HBV DNA in clinical samples. Applications of molecular diagnostics include identifying and profiling causative agents of infection and quantifying pathogens to monitor therapy durability. The sales of molecular diagnostics for infectious diseases, specifically HBV and HCV, represent a substantial share of the overall molecular diagnostics market.
Browse market data tables, figures, and in-depth TOC on “Hepatitis B and C Diagnostics Market” by Type (Immunodiagnostics, NAT) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2027. Download Free Sample
By Type, the Immunodiagnostics segment is projected to dominate the market size in 2024
ai_market_segmentation_by
By Geography, North America segment is expected to hold the largest market size for the year 2024
In the realm of infectious disease diagnostics, immunodiagnostic tests have emerged as a leading technology due to their ability to detect antigens or antibodies through an enzyme-triggered color change reaction. These tests are particularly effective in the diagnosis of Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections. The test commences with immobilizing the antigen from the sample onto a solid support, either non-specifically or specifically using capture antibodies. Subsequently, a detection antibody is introduced, forming a complex with the antigen. An enzymatic substrate is then applied, resulting in a visible signal proportional to the antigen quantity in the sample. The established presence of immunodiagnostics for an extended period has led to their highest adoption rates for HBV and HCV diagnosis.
North America is forecasted to hold the largest market size by region in 2024
The North American market for Hepatitis B and C diagnostics is projected to experience significant growth due to the rising incidence of infections in the region. According to a 2018 report by the Department of Health and Human Services (HHS), an estimated 850,000 individuals in the US were living with hepatitis B, with the actual number potentially reaching as high as 2.2 million or as low as 730,000, given that approximately 67% of infected individuals remain undiagnosed. The increasing demand for blood transfusions in North America, with approximately 4.5 million people requiring transfusions annually, has heightened the necessity for accurate and timely diagnosis of these viruses.
The Hepatitis B and C Diagnostics Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
Title: Hepatitis B and C Diagnostics Market: Advancements and Challenges in Detecting Chronic Infections The Hepatitis B and C diagnostics market is witnessing significant growth due to increasing awareness campaigns and advancements in diagnostic technologies. Hepatitis B (HBV) and C (HCV) are major public health concerns, with chronic infections affecting millions worldwide. HBV infection is diagnosed through HBsAg testing, while HCV infection is detected using HCV RNA testing. Nucleic acid testing, including nucleic acid assays and molecular diagnostics, plays a crucial role in the early detection of both chronic HBV and HCV infections. Liver biopsy and imaging tests, such as ultrasound and CT scans, are used to assess liver damage. However, these methods are invasive and have limitations. Rapid diagnostic tests, like ELISA and immunochromatographic assays, detect proteins, enzymes, antigens, and antibodies in blood samples. Vaccination coverage and blood transfusion donations are essential to prevent the spread of HBV. Nucleic acid tests, including HBV DNA testing and HCV RNA detection, are increasingly being used to improve diagnostic accuracy. Despite these advancements, challenges remain, including the high cost of molecular diagnostics and the need for standardized testing protocols.
Market Research Overview
The Hepatitis B and C diagnostics market encompasses a range of tests used for the detection and diagnosis of severe acute hepatitis caused by Hepatitis B (HBV) and C (HCV) viruses. Immunoassays, such as Enzyme-linked immunosorbent assay (ELISA) and Immunoassays, play a crucial role in the detection of HBsAg, HCV, and antibodies against these viruses. HBV DNA testing and HCV RNA detection are essential for diagnosing chronic HBV and HCV infections. Clinical laboratories and hospitals employ skilled technicians to perform these tests, ensuring proper sample procurement, transportation, storage, and cross-contamination prevention. Imaging tests, such as liver biopsy and imaging, complement diagnostic tests in assessing liver damage. Nucleic acid testing, including Polymerase chain reaction (PCR), and Next-Generation Sequencing, offer advanced pathogen detection capabilities. Awareness campaigns are vital for increasing vaccination coverage and early detection of HBV and HCV infections, particularly among adolescents and children. Diagnostic laboratories offer various tests, including rapid diagnostic tests, nucleic acid assays, and molecular diagnostics, to ensure accurate and timely results. Blood screening, blood transfusion, and donations are significant applications for these diagnostics. Reagents and kits, instruments, proteins, enzymes, antigens, and antibodies are essential components of Hepatitis B and C diagnostics. The market faces challenges such as the need for large laboratory space and the risk of errors due to human intervention. Ongoing research and technological advancements in this field continue to improve diagnostic accuracy and efficiency.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
